Edgewise Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Novo Holdings A/S reports a decrease in beneficial ownership of Edgewise Therapeutics, Inc. common stock to below the 5% threshold due to dilution.
NASDAQ
SCHEDULE 13D/A: OrbiMed Amends Edgewise Therapeutics Stake, Percentage Ownership Declines Due to Share Increase
OrbiMed Advisors and its affiliated entities have filed an Amendment No. 4 to their Schedule 13D, reporting a decrease in their beneficial ownership percentage of Edgewise Therapeutics, Inc. common stock to 14.5% due to an increase in the total outstanding shares of the issuer.